Table 3.
Demographic and baseline disease characteristics (confirmed influenza population)
| Placebo (n=89) | Nitazoxanide 300 mg (n=89) | Nitazoxanide 600 mg (n=79) | |
|---|---|---|---|
| Ethnic origin | |||
| White | 67 (75%) | 61 (68%) | 59 (75%) |
| Black | 10 (11%) | 13 (15%) | 11 (14%) |
| Hispanic | 6 (7%) | 11 (12%) | 5 (6%) |
| Other | 6 (7%) | 4 (5%) | 4 (5%) |
| Sex | |||
| Male | 43 (48%) | 40 (45%) | 36 (46%) |
| Age (years) | |||
| Mean (SD) | 32·2 (12·4) | 31·6 (12·9) | 33·2 (14·1) |
| Range | 12–65 | 12–63 | 12–66 |
| Smoker | |||
| Yes | 17 (19%) | 9 (10%) | 9 (11%) |
| Weight (kg) | |||
| Mean (SD) | 82·7 (24·9) | 80·8 (24·6) | 81·8 (23·3) |
| Range | 41–171 | 44–167 | 39–148 |
| BMI (kg/m2) | |||
| Mean (SD) | 28·9 (7·7) | 27·7 (7·0) | 28·1 (7·7) |
| Range | 17·3–55·7 | 16·8–54·5 | 13·9–52–6 |
| Duration of symptoms (h) | |||
| Mean (SD) | 28·1 (11·0) | 28·7 (12·5) | 27·3 (11·5) |
| Range | 5–50 | 3–49 | 4–59 |
| Cause of illness | |||
| Influenza A | 62 (70%) | 63 (71%) | 56 (71%) |
| 2009 H1N1 | 37 (42%) | 31 (35%) | 38 (48%) |
| H3N2 | 18 (20%) | 20 (22%) | 13 (16%) |
| Subtype undetermined | 7 (8%) | 12 (13%) | 5 (6%) |
| Influenza B | 26 (29%) | 26 (29%) | 22 (28%) |
| Influenza A and B | 1 (1%) | 0 | 1 (1%) |
| Oral temperature (°C) | |||
| Mean (SD) | 38·6 (0·4) | 38·6 (0·4) | 38·6 (0·4) |
| Range | 100–104 | 100–103 | 100–103 |
| Symptom severity score, median (95% CI) | |||
| Runny nose | 2 (1–2) | 1 (1–2) | 2 (1–2) |
| Nasal congestion | 2 (2–2) | 2 (2–2) | 2 (1–2) |
| Sore throat | 2 (2–2) | 2 (1–2) | 2 (1–2) |
| Cough | 2 (2–2) | 2 (2–3) | 2·5 (2–3) |
| Headache | 2 (2–2) | 2 (2–3) | 2 (2–2) |
| Myalgia | 2·5 (2–3) | 3 (2–3) | 2 (2–3) |
| Tiredness or fatigue | 3 (2–3) | 3 (2–3) | 3 (2–3) |
| Fever | 2 (1–2) | 3 (2–3) | 2 (2–3) |
| Sweats/chills | 2 (2–2) | 2 (2–3) | 2 (2–3) |
Data are n (%) unless otherwise indicated. BMI=body-mass index.